Abstract
We analyzed the frequencies of selection, the order of acquisition, and the mutations selected on moxifloxacin in two wild-type pneumococcal strains, R6 and 5714. The first selection step showed either a single GyrA mutation or no mutation in any of the quinolone resistance-determining regions. Second-step mutants selected had either a second mutation in ParC or in ParE. Moxifloxacin could belong to these fluoroquinolones, which preferentially target GyrA though probably acting equally through both gyrase and topoisomerase IV.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amino Acid Substitution
-
Anti-Infective Agents / pharmacology*
-
Aza Compounds*
-
DNA Gyrase / genetics
-
DNA Topoisomerase IV / genetics
-
DNA Topoisomerases, Type I / genetics*
-
Drug Resistance, Microbial
-
Fluoroquinolones*
-
Microbial Sensitivity Tests
-
Moxifloxacin
-
Mutation / genetics*
-
Quinolines*
-
Streptococcus pneumoniae / drug effects*
Substances
-
Anti-Infective Agents
-
Aza Compounds
-
Fluoroquinolones
-
Quinolines
-
DNA Topoisomerase IV
-
DNA Topoisomerases, Type I
-
DNA Gyrase
-
Moxifloxacin